本研究旨在利用甲殼素為基材製成熱敏感型水凝膠應用於肝癌之療效評估。甲殼素/甘油磷酸鹽(C/GP)水凝膠具備生物相容性及生物降解性且天然無毒性的優點,以水凝膠為載體與高能量貝他射線的錸-188及化療藥物Doxorubicin合併作為治療肝腫瘤藥物。本研究已完成C/GP/188Re-Tin colloid/Dox體外釋放,由實驗證實C/GP水凝膠系統可以有效地將藥物188Re-Tin colloid合併Dox 滯留進而達到延緩釋放長達48小時。然而,在C/GP/188Re-Tin colloid之動物體內生物分佈情形及初步的療效評估,由核醫造影研究中顯示C/GP/188Re-Tin colloid於直接腫瘤注射後至48小時仍無明顯擴散至其他器官。在療效評估方面,透過治療後大鼠肝腫瘤大小測量及肝臟病理切片實驗結果證實C/GP/188Re-Tin colloid能夠有效抑制腫瘤細胞生長而提高治療效果。
This study used chitosan as base for making thermosensitive and in situ formed hydrogel assessing the efficacy of treatment of liver cancer. Chitosan /β-glycerophosphate (C / GP) hydrogel is a biocompatible and biodegradable of a non-toxic and natural advantages, it can combined with rhenium -188 which include higher energy beta emission and doxorubicin (C/GP/188Re-Tin colloid/Dox)for the treatment of liver cancer. This study has been completed C/GP/188Re-Tin colloid / Dox in vitro release, confirmed by the experimental C / GP hydrogel system can be effectively combined 188Re-Tin colloid and Dox to achieve slow release of remaining live up to 48 hours. However, in C/GP/188Re-Tin colloid of animal bio-distribution and preliminary efficacy assessment by the nuclear medicine studies, also showed C/GP/188Re-Tin colloid directly to 48 hours after injection of tumor is still no significant proliferation. In the efficacy evaluation, tumor size, measured by liver biopsy and liver pathology results confirmed C/GP/188Re-Tin colloid could inhibit tumor cell growth and to improve treatment.